An innovative medical trial has found that delivering regenerative cells to developing infants suffering from spina bifida as part of a surgical repair may represent a "important advancement" in treating birth defects.
Study Parameters and Security
The American study involved six fetuses with a severe neural tube defect. Medical teams placed mother's placental stem cells directly onto the developing neural column while the defect was being closed.
Importantly, the cell therapy was found to be safe. The study team reported that the cells did not cause tumors, interfere with wound healing, or prevent the reversal of associated brain abnormalities.
Promising Outcomes
Post-birth MRI scans showed a successful correction of Chiari malformation in all six infants. This brain structure normalization is strongly associated with enhanced physical outcomes.
"In the event it allows a greater number of infants capable of walking who previously could not, it could establish itself as their standard of care," noted the study director. "The outcomes appear profoundly encouraging and create a pathway toward a variety of prospective novel therapies."
Future Implications and Hope
Commentators reviewing the findings have suggested that additional validation of these apparent benefits could herald a "different age" in in-utero treatment. The possibility of ameliorating neural deficits present before birth is considered a revolutionary objective.
Especially significant would be advancements for urogenital and gastrointestinal outcomes, which are frequent complications for those diagnosed with this condition.
Future Directions
Despite this being a first-in-human effort focused on a handful of cases, its confirmed tolerability and hopeful trends offer a robust platform for expanded clinical research. The addition of cellular treatment with established fetal surgery techniques offers substantial hope for changing life trajectories for future generations with spina bifida.